Cartesian Therapeutics, Inc. RNAC
Set alert
At close · Oct 30
After hours · Oct 30, 4:54 PM ET
- YTD
- -9.99%
- 1 year
- -19.98%
- Open
- 6.72
- Prev close
- 6.75
- Mkt cap
- 196.36M
- Vol
- 78.80K
- Avg vol
- 131.43K
- EPS
- -5.78
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.44
- High
- 6.76
- Forward P/E
- -5.54
- Beta
- 0.00
- Short ratio
- 15.83
- Inst. own
- 27.85%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 20.18
- 200-d avg
- 19.88
- 1y target
- 38.17
News
3 days ago seekingalpha.com
Cartesian: Maintaining 'Buy' On Descartes-08 MG Data Release And CAR-T Agreement
Cartesian Therapeutics maintains a 'Buy' rating, driven by advancing Descartes-08 cell therapy programs and imminent late-stage clinical catalysts. Topline results from the phase 3 AURORA study in…
2 weeks ago defenseworld.net
Cartesian Therapeutics (NASDAQ:RNAC) versus Syndax Pharmaceuticals (NASDAQ:SNDX) Critical Comparison
Syndax Pharmaceuticals (NASDAQ: SNDX - Get Free Report) and Cartesian Therapeutics (NASDAQ: RNAC - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We…
1 month ago globenewswire.com
Cartesian Therapeutics Announces New Employment Inducement Grants
FREDERICK, Md., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune…
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $25 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $25 price target.
-
1 month ago benzinga.com
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target
Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $40 price target.
-
1 month ago benzinga.com
Cartesian Therapeutics Presents Additional Retreatment Data Of Its Lead Investigational Asset, Descartes-08, In Patients With Generalized MG, During MGFA Scientific Session Of 2026 AANEM Annual Meeting
Descartes–08 demonstrated improvement in mean change from baseline in MG-ADL following initial treatment and retreatment; mean MG-ADL reduction of 6.6 points at Month 12 following retreatmentMedian…
1 month ago globenewswire.com
Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis
Descartes–08 demonstrated improvement in mean change from baseline in MG-ADL following initial treatment and retreatment; mean MG-ADL reduction of 6.6 points at Month 12 following retreatment
1 month ago globenewswire.com
Cartesian Therapeutics Announces New Employment Inducement Grants
FREDERICK, Md., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune…
1 month ago globenewswire.com
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
FREDERICK, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune…
-
2 months ago benzinga.com
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target
Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and maintains $38 price target.
2 months ago globenewswire.com
Cartesian Therapeutics Announces New Employment Inducement Grants
FREDERICK, Md., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune…
-
2 months ago benzinga.com
Cartesian Therapeutics Q2 EPS $0.46 Beats $(0.86) Estimate
Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $(0.86) by 153.49 percent. This is a 8 percent decrease over earnings…
2 months ago globenewswire.com
Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, biologics license application (BLA) filing planned for mid-2027
4 months ago globenewswire.com
Cartesian Therapeutics Announces New Employment Inducement Grants
FREDERICK, Md., July 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune…
4 months ago zacks.com
New Strong Sell Stocks for July 1st
CZR, RNAC and NSP have been added to the Zacks Rank #5 (Strong Sell) List on July 1, 2026.
4 months ago globenewswire.com
Cartesian Therapeutics Announces New Employment Inducement Grant
FREDERICK, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune…
4 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
4 months ago benzinga.com
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target
Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and maintains $38 price target.
4 months ago benzinga.com
New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease Market
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) stock is up on Tuesday as the company is announcing a strategic licensing agreement with WestGene Biopharma.
4 months ago benzinga.com
New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease Market
Cartesian Therapeutics gains after licensing an in vivo CAR-T platform from WestGene, with a myasthenia gravis trial planned for 2026.
4 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
4 months ago benzinga.com
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target
Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $40 price target.
-
4 months ago benzinga.com
BTIG Reiterates Buy on Cartesian Therapeutics, Maintains $44 Price Target
BTIG analyst Julian Harrison reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $44 price target.
4 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
4 months ago benzinga.com
Cartesian Therapeutics Inks Licensing Agreement With Westgene Biopharma For In Vivo Chimeric Antigen Receptor T-cell Therapies In Autoimmune Diseases, For Undisclosed Upfront And Milestone Payments
WestGene's established targeted LNP platform combined with Cartesian's mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid clinical translationPlans…
4 months ago globenewswire.com
Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases
WestGene's established targeted LNP platform combined with Cartesian's mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid clinical translation Plans…
-
5 months ago benzinga.com
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target
Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and maintains $38 price target.
-
5 months ago benzinga.com
Needham Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $40
Needham analyst Gil Blum maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and lowers the price target from $42 to $40.
-
5 months ago benzinga.com
Cartesian Therapeutics Announces Non-Dilutive Financing Of Up To $150M From K2 HealthVentures; Expects Topline Data From Phase 3 AURORA Trial In Q1 2027
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that it has entered into an…
5 months ago globenewswire.com
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million from initial tranche extends cash runway into 2028 Financing strengthens Cartesian's financial…
5 months ago globenewswire.com
Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
FREDERICK, Md., May 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune…
-
5 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $25
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and lowers the price target from $30 to $25.
6 months ago globenewswire.com
Cartesian Therapeutics Announces New Employment Inducement Grants
FREDERICK, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune…
-
6 months ago benzinga.com
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target
Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and maintains $38 price target.
6 months ago zacks.com
Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue Estimates
Cartesian Therapeutics, Inc. (RNAC) came out with a quarterly loss of $1.46 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to a loss of $0.68 per share a year ago.
-
6 months ago benzinga.com
Cartesian Therapeutics Q1 EPS $(1.46) Misses $(0.88) Estimate, Sales $78.000K Miss $99.833K Estimate
Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of $(0.88) by 65.91 percent. This is a 114.71 percent decrease over…
6 months ago globenewswire.com
Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome initiated Multiple…
6 months ago seekingalpha.com
Cartesian Therapeutics: A Phase 3 mRNA CAR-T Bet
Cartesian Therapeutics receives a buy rating, driven by a differentiated mRNA CAR-T approach for autoimmune diseases and strong insider/institutional support. RNAC's lead asset, Descartes-08,…
-
7 months ago benzinga.com
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target
Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and maintains $38 price target.
-
7 months ago benzinga.com
Cantor Fitzgerald Upgrades Cartesian Therapeutics to Overweight, Announces $16 Price Target
Cantor Fitzgerald analyst Kristen Kluska upgrades Cartesian Therapeutics (NASDAQ:RNAC) from Neutral to Overweight and announces $16 price target.
-
7 months ago benzinga.com
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $42 Price Target
Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $42 price target.
-
7 months ago benzinga.com
CORRECTION: Cartesian Therapeutics Q4 Adj. EPS $(1.39) Misses $(0.85) Estimate, Sales $947.00K Beat $94.67K Estimate. Adj. EPS excludes Impairment Charges Of $56.7M
Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(0.85) by 62.95 percent. This is a 247.5 percent decrease over…
7 months ago benzinga.com
Insights into Cartesian Therapeutics Q4 Earnings
Insights into Cartesian Therapeutics Q4 Earnings
-
9 months ago benzinga.com
Needham Maintains Buy on Cartesian Therapeutics, Raises Price Target to $42
Needham analyst Gil Blum maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and raises the price target from $40 to $42.
9 months ago benzinga.com
Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment
Johnson & Johnson reported encouraging Phase 2 results for its experimental lupus drug nipocalimab in patients with SLE.
-
11 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $30
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and lowers the price target from $40 to $30.
11 months ago benzinga.com
Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus
Cartesian Therapeutics shared initial data from Phase 2 trial of Descartes-08, showing potential for treating systemic lupus erythematosus.
11 months ago benzinga.com
Nvidia To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday
Nvidia To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday
-
11 months ago benzinga.com
BTIG Maintains Buy on Cartesian Therapeutics, Raises Price Target to $44
BTIG analyst Julian Harrison maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and raises the price target from $42 to $44.
-
11 months ago benzinga.com
Cartesian Therapeutics Data From Phase 2 Study Of Descartes-08 Demonstrates 100% Lupus Low Disease Activity State Response Rate In Participants With Systemic Lupus Erythematosus
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced positive initial data from the…